Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benadryl springs into allergy season

This article was originally published in The Tan Sheet

Executive Summary

New ads for Warner-Lambert's Benadryl allergy products touting effectiveness compared to Rx remedies broke March 13 with a 30-second TV spot. "It may surprise you to know, medical studies prove histamine-blocking Benadryl to be a full 54% more effective than the leading prescription," the ad claims. Allergy drug maker Schering-Plough compared its Rx antihistamine Claritin to OTCs such as Benadryl last year, claiming Claritin does not cause drowsiness (1"The Tan Sheet" Jan. 4, 1999, p. 7). W-L extended Benadryl recently with Children's Fastmelt (2"The Tan Sheet" March 13, p. 8)
Advertisement

Related Content

Benadryl Children's Allergy/Cold Line Adding Fastmelt Quick-Dissolve Form
Claritin DTC Ad Spend Totals $148 Mil. In Recent 12 Months - Scott-Levin
Claritin DTC Ad Spend Totals $148 Mil. In Recent 12 Months - Scott-Levin

Topics

Advertisement
UsernamePublicRestriction

Register

PS091007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel